sevikar medication Uses, Dosage, Side Effects, Precautions & Warnings

sevikar 20/5 mg
0

Generic  drug of the Therapeutic class: Cardiology and angiology
Active ingredients: Olmesartan medoxomil , Amlodipine 

what is Sevikar ?

SEVIKAR is used to treat high blood pressure (hypertension) in patients whose blood pressure is not adequately controlled with either olmesartan medoxomil or amlodipine, each given alone.

PRESENTATION (S) AVAILABLE FOR SEVIKAR 20 MG / 5 MG

3 presentations are available for this drug:

  • polyamide aluminum PVC-Aluminum blister pack (s) of 30 tablet (s)
  • polyamide aluminum PVC-Aluminum blister pack (s) of 50 tablet (s)
  • polyamide aluminum PVC-Aluminum blister pack (s) of 90 tablet (s)
FEATUREDESCRIPTION
Pharmaceutical classsubstances that affect the renin-angiotensin system
Active substance (s)for one tablet: olmesartan medoxomil (20 mg), amlodipine besilate (6.944 mg)
General medicineno
Pharmaceutical formcoated tablet
Route (s) of administrationoral
Social security reimbursement rate65%
Laboratory (s)DAIICHI SANKYO FRANCE SAS
Conditions of issueavailable by simple prescription

what is Sevikar medication used for and indication?

Treatment of essential hypertension.

SEVIKAR is indicated in adult patients whose blood pressure is not adequately controlled with olmesartan medoxomil or amlodipine as monotherapy ( Pharmacodynamic properties).

Sevikar Dosage

Dosage

Adults

  • The recommended dose of SEVIKAR is one tablet per day.
  • SEVIKAR 40 mg / 10 mg film-coated tablets can be administered to patients whose blood pressure is not adequately controlled by SEVIKAR 40 mg / 5 mg.
  • A gradual adjustment of the dose of each component is recommended before switching to the fixed dose combination. A direct switch from monotherapy to a fixed dose combination may be considered if it is clinically justified.
  • For convenience, patients taking olmesartan medoxomil and amlodipine separately as tablets may instead take the strength of SEVIKAR tablet corresponding to the same doses of these two components.
  • SEVIKAR can be taken with or without food.

Elderly subjects (65 years and over)

  • In most cases, no dosage adjustment of the recommended dose is required in the elderly, but any increase in dosage should be done with caution (see sections 4.4 and Pharmacokinetics). If an increase to the maximum dose of 40 mg olmesartan medoxomil per day is necessary, blood pressure should be closely monitored.

Renal failure

  • In patients with mild to moderate renal impairment (creatinine clearance 20-60 ml / min), the maximum dose of olmesartan medoxomil is 20 mg once daily, taking into account the limited experience of patients. higher dosages in this group of patients. In patients with severe renal impairment (creatinine clearance <20 ml / min) the use of SEVIKAR is not recommended (see sections 4.4 and Pharmacokinetic properties). In patients with moderate renal impairment, it is advisable to monitor potassium and creatinine levels.

Hepatic insufficiency

  • SEVIKAR should be used with caution in patients with mild to moderate hepatic impairment ( Pharmacokinetic properties).
  • In patients with moderate hepatic impairment, the recommended starting dose of olmesartan medoxomil is 10 mg once daily and the maximum dose is 20 mg once daily. Close monitoring of blood pressure and renal function is recommended in patients with hepatic impairment already treated with diuretics and / or other antihypertensive drugs. There is no experience with the use of olmesartan medoxomil in patients with severe hepatic impairment.
  • As with any calcium channel blocker, the half-life of amlodipine is prolonged in patients with impaired hepatic function and dosage recommendations have not been established. Therefore, SEVIKAR should be administered with caution in these patients. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be started at the lowest dose and increased slowly in patients with severe hepatic impairment. The use of SEVIKAR in patients with severe hepatic impairment is contraindicated .

Pediatric population

  • The safety and efficacy of SEVIKAR in children and adolescents below 18 years of age have not been established. No data is available.

Administration mode

  • The tablet should be swallowed with a sufficient amount of liquid (eg a glass of water). The tablet should not be chewed and should be taken at the same time each day.

Sevikar Contraindications

Hypersensitivity to the active substances, to dihydropyridines or to any of the excipients (see section Composition ).

2 nd and 3 rd trimesters of pregnancy (see sections Warnings and precautions for use and Pregnancy and breast-feeding ).

Severe hepatic impairment and obstruction of the bile ducts.

Due to the presence of amlodipine, SEVIKAR is also contraindicated in patients with:

  • Severe hypotension,
  • shock (including cardiogenic shock),
  • An obstruction of the outflow path of the left ventricle (for example high-grade aortic stenosis),
  • Hemodynamically unstable heart failure after acute myocardial infarction.

how does Sevikar work?

Pharmacotherapeutic group: angiotensin II antagonists and calcium channel blockers, ATC code: C09DB02 .

Action mechanism

  • SEVIKAR combines an angiotensin II receptor antagonist, olmesartan medoxomil, with a calcium channel blocker, amlodipine besilate. The combination of these active substances has a synergistic antihypertensive effect, lowering blood pressure more significantly than each of the components administered alone.

Clinical efficacy and safety

SEVIKAR

  • In a double-blind, randomized, placebo-controlled factorial trial, including 1940 patients (71% of Caucasian origin and 29% of non-Caucasian origin) for 8 weeks, treatment with the different strengths of SEVIKAR resulted in significant reductions higher diastolic and systolic blood pressure compared to the respective monotherapies of the components. The mean reduction in systolic / diastolic blood pressure was dose-dependent: -24 / -14 mmHg (20 mg / 5 mg combination), -25 / -16 mmHg (40 mg / 5 mg combination) and -30 / -19 mmHg (combination 40 mg / 10 mg). SEVIKAR 40 mg / 5 mg resulted in an additional reduction in systolic / diastolic blood pressure when sitting by 2.5 / 1.7 mmHg compared to SEVIKAR 20 mg / 5 mg. Likewise, SEVIKAR 40 mg / 10 mg resulted in an additional reduction in systolic / diastolic blood pressure when sitting by 4.7 / 3.5 mmHg compared to SEVIKAR 40 mg / 5 mg. The proportion of patients achieving systolic and diastolic blood pressure target values ​​(<140/90 mmHg in non-diabetic patients and <130/80 mmHg in diabetic patients) was 42.5%, 51.0% and 49.1% for SEVIKAR 20 mg / 5 mg, for SEVIKAR 40 mg / 5 mg and for SEVIKAR 40 mg / 10 mg. Most of the antihypertensive effect of SEVIKAR was usually achieved within the first 2 weeks of treatment. The proportion of patients achieving systolic and diastolic blood pressure target values ​​(<140/90 mmHg in non-diabetic patients and <130/80 mmHg in diabetic patients) was 42.5%, 51.0% and 49.1% for SEVIKAR 20 mg / 5 mg, for SEVIKAR 40 mg / 5 mg and for SEVIKAR 40 mg / 10 mg. Most of the antihypertensive effect of SEVIKAR was usually achieved within the first 2 weeks of treatment. The proportion of patients achieving systolic and diastolic blood pressure target values ​​(<140/90 mmHg in non-diabetic patients and <130/80 mmHg in diabetic patients) was 42.5%, 51.0% and 49.1% for SEVIKAR 20 mg / 5 mg, for SEVIKAR 40 mg / 5 mg and for SEVIKAR 40 mg / 10 mg. Most of the antihypertensive effect of SEVIKAR was usually achieved within the first 2 weeks of treatment.
  • A second double-blind, randomized, placebo-controlled trial evaluated the effectiveness of adding amlodipine in patients of Caucasian origin whose blood pressure was insufficiently controlled with olmesartan medoxomil 20 mg as monotherapy for 8 weeks. In patients who continued to receive 20 mg olmesartan medoxomil alone, systolic / diastolic blood pressure was reduced by -10.6 / -7.8 mmHg after an additional 8 weeks of treatment. Addition of amlodipine 5 mg for 8 weeks resulted in a reduction in systolic / diastolic blood pressure of -16.2 / -10.6 mmHg (p = 0.0006). The proportion of patients achieving blood pressure targets (<140/90 mmHg in non-diabetic patients and <
  • An additional trial evaluated the addition of different doses of olmesartan medoxomil in patients of Caucasian origin whose blood pressure was insufficiently controlled with amlodipine 5 mg as monotherapy for 8 weeks. In patients who continued to receive 5 mg amlodipine alone, systolic / diastolic blood pressure was reduced by -9.9 / -5.7 mmHg after an additional 8 weeks. Addition of olmesartan medoxomil 20 mg resulted in a reduction in systolic / diastolic blood pressure of -15.3 / -9.3 mmHg and addition of olmesartan medoxomil 40 mg resulted in a reduction in systolic blood pressure / diastolic of -16.7 / -9.5 mmHg (p <0.0001). The proportions of patients achieving blood pressure targets (<
  • No randomized study comparing, in uncontrolled hypertensive patients, the use of medium doses of SEVIKAR versus increasing doses up to the maximum dose of amlodipine or olmesartan as monotherapy is not available.
  • These 3 trials confirmed that the drop in blood pressure induced by SEVIKAR administered once a day is maintained over 24 hours, with valley-peak ratios of 71% to 82% for systolic and diastolic responses and efficacy over 24 hours a was confirmed by ambulatory blood pressure measurement.
  • The antihypertensive effect of SEVIKAR is the same regardless of age and sex, and whether or not the patients have diabetes.
  • In 2 extensions of open-label and non-randomized trials, maintenance of the efficacy of SEVIKAR 40 mg / 5 mg has been demonstrated at one year in 49 to 67% of patients.

Olmesartan medoxomil (active substance in SEVIKAR)

  • Olmesartan medoxomil, a component of SEVIKAR, is a selective angiotensin II (AT1) type 1 receptor antagonist. Olmesartan medoxomil is rapidly transformed into the pharmacologically active metabolite, olmesartan. Angiotensin II is the main vasoactive hormone of the renin-angiotensin-aldosterone system. It plays an important role in the pathophysiology of hypertension. The effects of angiotensin II are vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal sodium reabsorption. Olmesartan blocks the vasoconstrictor effects of angiotensin II and those related to the secretion of aldosterone by blocking its binding to AT1 receptors present in tissues such as vascular smooth muscles and adrenal glands. The effect of olmesartan is independent of the origin or the route of synthesis of angiotensin II. Selective antagonism of angiotensin II (AT1) receptors by olmesartan results in increased plasma renin levels and angiotensin I and II concentrations, as well as decreased plasma concentrations of aldosterone.
  • In hypertensive patients, olmesartan medoxomil causes a dose-dependent and lasting decrease in blood pressure. No hypotension related to the first dose, no case of tachyphylaxis during prolonged administration, nor any rebound effect on abrupt discontinuation of treatment were observed.
  • In hypertensive patients, administration of a daily dose of olmesartan medoxomil produces a gradual and effective decrease in blood pressure over 24 hours. At an equivalent total daily dose, administration in 1 or 2 doses results in the same decrease in blood pressure.
  • With continuous treatment, the maximum decrease in blood pressure is achieved 8 weeks after the start of treatment, although a significant drop in blood pressure is already observed after 2 weeks of treatment.
  • The effect of olmesartan medoxomil on mortality and morbidity is not yet known.
  • The ROADMAP study (Randomized Olmesartan and Diabetes Microalbuminuria Prevention study, Study evaluating olmesartan medoxomil in the prevention of microalbuminuria in type II diabetic patients) carried out in 4447 patients with type 2 diabetes, normoalbuminuria and having at least an additional cardiovascular risk factor, assessed whether treatment with olmesartan medoxomil could delay the onset of microalbuminuria. During a median follow-up period of 3.2 years, patients received olmesartan medoxomil or placebo in addition to other antihypertensive drugs, except angiotensin II converting enzyme inhibitors and angiotensin II receptor antagonists.
  • For the primary endpoint, the study demonstrated a significant reduction in the time to onset of microalbuminuria, in favor of olmesartan medoxomil. After adjusting for blood pressure level, this risk reduction was no longer statistically significant. 8.2% (178 out of 2160) of patients in the olmesartan medoxomil group and 9.8% (210 out of 2139) of patients in the placebo group developed microalbuminuria.
  • For secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) on olmesartan medoxomil and in 94 patients (4.2%) on placebo. The incidence of cardiovascular mortality was higher with olmesartan medoxomil compared to placebo (15 patients (0.7%) versus 3 patients (0.1%)), despite similar rates of non-fatal stroke (14 patients (0.6%) versus 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) versus 26 patients (1.2%)) and mortality non-cardiovascular (11 patients (0.5%) versus 12 patients (0.5%)). The overall mortality with olmesartan medoxomil was increased in number of cases (26 patients (1.2%) versus 15 patients (0.7%)), mainly due to a higher number of fatal cardiovascular events.
  • The ORIENT study (Olmesartan Reducing Incidence of End-stage Renal disease in Diabetic Nephropathy Trial, Study to evaluate olmesartan medoxomil in secondary prevention in diabetic patients with nephropathy) evaluated the effects of olmesartan medoxomil on renal and cardiovascular events in 577 patients, randomized, Japanese and Chinese, with type 2 diabetes with established nephropathy. During a median follow-up period of 3.1 years, patients received olmesartan medoxomil or placebo in addition to other antihypertensive drugs, including angiotensin II converting enzyme inhibitors.
  • The primary composite endpoint (time to onset of first event of serum creatinine doubling, end stage renal disease and all-cause death) occurred in 116 patients in the olmesartan medoxomil group (41.1%) and in 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI [0.75 to 1.24]); p = 0.791). The composite secondary cardiovascular endpoint occurred in 40 patients treated with olmesartan medoxomil (14.2%) and 53 patients treated with placebo (18.7%). This composite cardiovascular endpoint included cardiovascular deaths in 10 (3.5%) patients receiving olmesartan medoxomil versus 3 (1.1%) patients receiving placebo, overall mortality in 19 (6.7%) patients versus 20 (7.0%), non-fatal stroke in 8 (2.8%) patients versus 11 (3,

Amlodipine (active substance in SEVIKAR)

  • Amlodipine, a component of SEVIKAR, is a calcium channel blocker that inhibits transmembrane entry of calcium ions through potential-dependent L-type channels in heart muscle and vascular smooth muscle. Experimental data indicate that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. Amlodipine has a relatively selective effect at the vessel level, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. The antihypertensive effect of amlodipine results from a direct relaxing effect at the level of vascular smooth muscle, which leads to a reduction in peripheral resistance and, therefore, in blood pressure.
  • In hypertensive patients, amlodipine causes a dose-dependent and lasting decrease in blood pressure. No hypotensive effect associated with the first dose, nor tachyphylaxis in the event of prolonged administration has been described. No rebound effect upon abrupt discontinuation of treatment was observed.
  • After administration of therapeutic doses to hypertensive patients, amlodipine results in an effective reduction in blood pressure when lying, sitting or standing. Long-term use of amlodipine is not associated with a significant change in heart rate or in plasma catecholamine levels. In hypertensive patients with normal renal function, therapeutic doses of amlodipine decrease renal vascular resistance and increase glomerular filtration rate as well as efficient renal plasma flow, without modification of filtration fraction or proteinuria.
  • In hemodynamic studies in patients with heart failure and in clinical trials based on stress tests in patients with NYHA stage III to IV heart failure, amlodipine did not cause of clinical deterioration as evidenced by resistance exercise, left ventricular ejection fraction, and by clinical signs and symptoms.
  • A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA-classified stage III to IV heart failure receiving digoxin, diuretics and angiotensin converting enzyme inhibitors , showed that amlodipine did not increase the risk of mortality or the combined risk of mortality and morbidity in these patients with heart failure.
  • In a long-term, placebo-controlled, follow-up study (PRAISE-2) evaluating amlodipine in patients with stage III to IV heart failure according to the NYHA classification without clinical symptoms or objective findings suggestive of underlying ischemia, treated with stable doses of angiotensin converting enzyme inhibitors, digitalis, and diuretics, amlodipine had no effect on total or cardiovascular mortality. In this same population, amlodipine was associated with an increase in reported cases of pulmonary edema, although the difference in the incidence of worsening heart failure was not significant compared to placebo.
  • Study on the preventive treatment of heart failure (Treatment to Prevent Heart Attack Trial, ALLHAT).
  • The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), randomized, double-blind, morbidity and mortality study was performed to compare treatments recent: amlodipine 2.5 to 10 mg / day (calcium channel blocker) or lisinopril 10 to 40 mg / day (ACE inhibitor) as first-line treatment compared to a thiazide diuretic, chlortalidone at a dose of 12, 5 to 25 mg / day in mild to moderate hypertension.
  • A total of 33,357 hypertensive patients aged 55 or over were randomized and followed for an average of 4.9 years. Patients had at least one risk factor for additional coronary artery disease, including: history of myocardial infarction or stroke (more than six months prior to inclusion) or documentation of other atherosclerotic cardiovascular disease (in total 51.5%), type 2 diabetes (36.1%), HDL cholesterol <35 mg / dl (11.6%), left ventricular hypertrophy diagnosed by electrocardiography or echocardiography (20.9%), current smoking (21 , 9%). The primary composite endpoint was fatal coronary artery disease or non-fatal myocardial infarction. It does no significant difference was observed in the primary endpoint between treatment with amlodipine and treatment with chlortalidone: RR: 0.98; 95% CI[ 0.90 to 1.07 ]  ; p = 0.65. Among the secondary endpoints, the incidence of heart failure (part of a composite cardiovascular endpoint) was significantly higher in the amlodipine group compared to the chlortalidone group (10.2% versus 7, 7%; RR: 1.38; 95% CI [ 1.25 to 1.52 ]; p <0.001). However, no significant difference was observed in the mortality from any cause between treatment with amlodipine and treatment with chlortalidone: RR: 0.96; 95% CI [ 0.89 to 1.02 ]  ; p = 0.20.

Other information

  • The use of the combination of an ACE inhibitor with an angiotensin II receptor antagonist (ARAII) has been analyzed in two large randomized controlled trials (ONTARGET (ONgoing Telmisartan) Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)).
  • The ONTARGET study was performed in patients with a history of cardiovascular disease or cerebrovascular disease, or type 2 diabetes with target organ damage. The VA NEPHRON-D study was performed in patients with type 2 diabetes and diabetic nephropathy.
  • In comparison with monotherapy, these studies did not demonstrate a significant beneficial effect on the evolution of renal and / or cardiovascular damage and on mortality, while an increased risk of hyperkalaemia was observed. , acute renal failure and / or hypotension.
  • These results are also applicable to other ACE inhibitors and ARAIIs, given the similarity of their pharmacodynamic properties.
  • ACE inhibitors and ARBs should therefore not be combined in patients with diabetic nephropathy.
  • The ALTITUDE study (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was conducted to assess the benefit of adding aliskiren to standard ACE inhibitor or ARBIA therapy in patients with ” type 2 diabetes and chronic renal failure, with or without cardiovascular disorders. This study was terminated prematurely due to an increased risk of adverse events. Cardiovascular deaths and strokes were more common in the aliskiren group than in the placebo group; likewise adverse events and certain serious adverse events such as hyperkalaemia, hypotension and

 

How To Store Sevikar ?

  • Keep this medication out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the package after “EXP”. The expiration date refers to the last day of that month.
  • This product does not require any special storage conditions.
  • Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

What are the side effects of sevikar?

SEVIKAR

  • The most frequently reported side effects during treatment with SEVIKAR are peripheral edema (11.3%), headache (5.3%) and dizziness (4.5%).
  • The adverse reactions observed with SEVIKAR in clinical trials, safety studies after marketing authorization and spontaneous reports are summarized in the table below, as well as the adverse reactions reported with any of the ingredients. , olmesartan medoxomil and amlodipine, given the known safety profiles of these substances.

The following definitions have been used in order to rank the frequency of adverse reactions:

  • Very common (≥ 1/10)
  • Common (≥ 1/100 to <1/10)
  • Uncommon (≥ 1/1000 to <1/100)
  • Rare (≥ 1 / 10,000 to <1 / 1,000)
  • Very rare (<1 / 10,000)

Not known (frequency cannot be estimated from the available data)

MedDRA System Organ Classes

Side effectsFrequency
Olmesartan medoxomil / amlodipine combinationOlmesartan medoxomilAmlodipine

Blood and lymphatic system disorders

Leukocytopenia

Very rare

Thrombocytopenia

Rare

Very rare

Immune system disorders

Allergic reaction / Hypersensitivity to the product

Rare

Very rare

Anaphylactic reaction

Rare

Metabolism and nutrition disorders

Hyperglycemia

Very rare

Hyperkalaemia

Rare

Rare

Hypertriglyceridemia

Frequent

Hyperuricemia

Frequent

Psychiatric disorders

Confusion

Rare

Depression

Rare

Insomnia

Rare

Irritability

Rare

Decreased libido

Rare

Mood changes (including anxiety)

Rare

Nervous system disorders

Vertiginous sensations

Frequent

Frequent

Frequent

Dysgeusia

Rare

Headache

Frequent

Frequent

Common (especially at the start of treatment)

Hypertonia

Very rare

Hypoaesthesia

Rare

Rare

Lethargy

Rare

Paresthesia

Rare

Rare

Peripheral neuropathy

Very rare

Dizzying postural sensations

Rare

Sleeping troubles

Rare

Drowsiness

Frequent

Syncope

Rare

Rare

Tremors

Rare

Eye disorders

Visual disturbances (including diplopia)

Rare

Ear and labyrinth disorders

Tinnitus

Rare

Dizziness

Rare

Rare

Cardiac disorders

Angina pectoris

Rare

Uncommon (including worsening of angina pectoris)

Arrhythmias (including bradycardias, ventricular tachycardias and atrial fibrillations)

Very rare

Myocardial infarction

Very rare

Palpitations

Rare

Rare

Tachycardia

Rare

Vascular disorders

Hypotension

Rare

Rare

Rare

Orthostatic hypotension

Rare

Flushing

Rare

Frequent

Vasculitis

Very rare

Respiratory, thoracic and mediastinal disorders

Bronchitis

Frequent

Cough

Rare

Frequent

Very rare

Dyspnea

Rare

Rare

Pharyngitis

Frequent

Rhinitis

Frequent

Rare

Gastrointestinal disorders

Abdominal pain

Frequent

Frequent

Changes in bowel movement (including diarrhea and constipation)

Rare

Constipation

Rare

Diarrhea

Rare

Frequent

Dry mouth

Rare

Rare

Dyspepsia

Rare

Frequent

Rare

Gastritis

Very rare

Gastroenteritis

Frequent

Gingival hyperplasia

Very rare

Nausea

Rare

Frequent

Frequent

Pancreatitis

Very rare

Epigastric pain

Rare

Vomiting

Rare

Rare

Rare

Hepatobiliary disorders

Increased liver enzymes

Frequent

Very rare (usually associated with cholestasis)

Hepatitis

Very rare

Jaundice

Very rare

Skin and subcutaneous tissue disorders

Alopecia

Rare

Angioneurotic edema

Rare

Very rare

Allergic dermatitis

Rare

Erythema multiforme

Very rare

Exanthema

Rare

Rare

Exfoliative dermatitis

Very rare

Hyperhidrosis

Rare

Photosensitivity

Very rare

Pruritus

Rare

Rare

Purpura

Rare

Angioedema

Very rare

Rash

Rare

Rare

Rare

Skin discoloration

Rare

Stevens Johnson Syndrome

Very rare

Urticaria

Rare

Rare

Very rare

Musculoskeletal and connective tissue disorders

Ankle swelling

Frequent

Arthralgia

Rare

Arthritis

Frequent

Back pain

Rare

Frequent

Rare

Muscle spasms

Rare

Rare

Rare

Myalgia

Rare

Rare

Pain in extremity

Rare

Bone pain

Frequent

Kidney and urinary tract disorders

Acute renal failure

Rare

Haematuria

Frequent

Increased voiding frequency

Rare

Urination disorders

Rare

Nocturia

Rare

Pollakiuria

Rare

Renal failure

Rare

Urinary tract infection

Frequent

Reproductive system and breast disorders

Erectile dysfunction / impotence

Rare

Rare

Gynecomastia

Rare

General disorders and administration site conditions

Asthenia

Rare

Rare

Rare

Chest pain

Frequent

Rare

Face edema

Rare

Rare

Tired

Frequent

Frequent

Frequent

Flu syndrome

Frequent

Lethargy

Rare

Discomfort

Rare

Rare

Edema

Frequent

Frequent

Pain

Frequent

Rare

Peripheral edema

Frequent

Frequent

Edema taking the scoop

Frequent

Investigations

Hypercreatininaemia

Rare

Rare

Increased blood creatine phosphokinase

Frequent

Hypokalaemia

Rare

Increased blood urea

Frequent

Hyperuricemia

Rare

Increased gamma-GT

Rare

Weightloss

Rare

Weight gain

Rare

  • Isolated cases of rhabdomyolysis have been reported with combinations comprising angiotensin II receptor antagonists. Isolated cases of extrapyramidal syndrome have been reported in patients treated with amlodipine.

Sevikar Interactions

Taking other medications

Please tell your doctor or pharmacist if you are taking or have recently taken any of the following medicines:

  • Potassium supplements, salt substitutes containing potassium, medicines that increase the amount of urine you make(diuretics), or heparin (to thin the blood and prevent blood clots). Using these medicines together with SEVIKAR may increase the potassium levels in your blood.
  • Lithium(a medicine used to treat mood changes and some types of depression). Using this medicine at the same time as SEVIKAR may increase the toxicity of lithium. If you need to take lithium, your doctor will measure your blood lithium level.
  • Nonsteroidal anti-inflammatory drugs(NSAIDs, medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis). Using these medicines together with SEVIKAR may increase the risk of kidney failure. The effect of SEVIKAR may be reduced by NSAIDs.
  • Other medicines which lower blood pressure, the use of which may increase the effect of SEVIKAR.
  • Certain antacids(treatment for heartburn or indigestion), the use of which may slightly decrease the effect of SEVIKAR.
  • Medicines used in HIV / AIDS(eg: ritonavir, indinavir, nelfinavir) or the treatment of yeast infections (eg: ketoconazole, itraconazole).
  • Diltiazem, verapamil(substances used in arrhythmias and high blood pressure).
  • Rifampicinerythromycin, clarithromycin (substances used in tuberculosis or other infections).
  • John’s Wort (Hypericum perforatum) extract, (herbal remedy).
  • Dantrolene(infusion for severe increases in body temperature).
  • Simvastatin, asubstance used to lower the levels of cholesterol and fats (triglycerides) in the blood.

If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist.

INTERACTIONS OF SEVIKAR 20 MG / 5 MG WITH FOOD AND DRINK

Food and drinks

  • SEVIKAR can be taken with or without food. Swallow the tablet with a liquid (such as a glass of water). If possible, take your daily dose at the same time each day, for example at breakfast time.
  • Grapefruit juice and grapefruit should not be consumed by people taking SEVIKAR. This is because grapefruit and grapefruit juice can cause increased blood levels of the active substance, amlodipine, which can cause an unpredictable increase in the antihypertensive effect of SEVIKAR.

Drive and use machines

  • You may feel sleepy, sick, feel dizzy, or have a headache when you are being treated for high blood pressure. If this happens to you, do not drive or use machines until your symptoms are gone. Ask your doctor for advice.
  • This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free’.
  • SEVIKAR 20 mg / 5 mg film-coated tablets contain <{name the excipient (s)}>
  • Not applicable.

Warnings and Precautions

Take special care with SEVIKAR 20 mg / 5 mg film-coated tablets:

Before taking these tablets, tell your doctor if you have any of the following:

  • Kidney problems or kidney transplant.
  • Liver disease.
  • Heart failure or problems with your heart valves or heart muscle.
  • Severe vomiting, diarrhea, high dose treatment with medicines that increase the amount of urine you make (diuretics) or if you are on a low salt diet.
  • High levels of potassium in your blood.
  • Problems with your adrenal glands (hormone-producing glands above the kidneys).

As with any medicine that lowers blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances to the heart or brain can lead to a heart attack or stroke. Your doctor should therefore carefully check your blood pressure.

You must tell your doctor if you think you are (or might become) pregnant. SEVIKAR is not recommended in early pregnancy and should not be taken if you are more than 3 months pregnant, as it could seriously harm your child if used from this stage of pregnancy.

Children and adolescents

SEVIKAR is not recommended for children and adolescents under 18 years old.

Older subjects

If you are over 65, your doctor should check your blood pressure regularly with each dose increase to make sure that your blood pressure is not getting too low.

Black patients

As with other similar medicines, the effect of SEVIKAR in lowering blood pressure may be somewhat weaker in black patients.

PREGNANCY & BREAST-FEEDING & FERTILITY

Ask your doctor or pharmacist for advice before taking any medicine.

Pregnancy

  • You must tell your doctor if you think you are (or might become) pregnant . Your doctor will normally recommend that you stop taking SEVIKAR before you become pregnant or as soon as you find out that you are pregnant. Your doctor will recommend that you take another medicine instead of SEVIKAR. SEVIKAR is not recommended in early pregnancy and should not be taken after more than 3 months of pregnancy as this could seriously harm your child.
  • If you become pregnant while taking SEVIKAR, you should inform and consult your doctor without delay.

Feeding with milk

  • Tell your doctor if you are breast-feeding or about to start breast-feeding. SEVIKAR is not recommended for women who are breastfeeding, your doctor may choose another treatment if you want to breastfeed, especially if your baby is newborn or premature.

What happens if I overdose from Sevikar ?

  • If you take more tablets than you should your blood pressure may become low and you may experience symptoms such as dizziness; a slow or fast heartbeat.
  • If you take more tablets than you should or if a child accidentally swallows them, go to your doctor or nearest emergency department immediately and take the medicine pack or this leaflet with you.

What should I do if I miss a dose?

  • If you forget to take a dose, take the next dose at the usual time. Do not take a double dose to make up for the dose you forgot to take.

What happens if you stop taking Sevikar ?

If you stop taking SEVIKAR 20 mg / 5 mg film-coated tablets:

  • It is important to keep taking SEVIKAR unless your doctor tells you to stop.
  • If you have further questions on the use of this medicine, ask your doctor or pharmacist for more information.

What is  Forms and Composition ?

Forms

  • Coated tablet.
  • Brownish red, round, 8 mm film-coated tablet, marked with “C77” on one side.
  • 14, 28, 30, 56, 90, 98, 10 × 28 and 10 × 30 film-coated tablets in blister packs (Polyamide / Aluminum / PVC / Aluminum).
  • 10, 50 and 500 film-coated tablets in individual blister packs (Polyamide / Aluminum / PVC / Aluminum).
  • Not all presentations may be marketed.

Other shapes

  • SEVIKAR 40 mg / 10 mg, film-coated tablet, box of 30
  • SEVIKAR 40 mg / 5 mg, film-coated tablet, box of 30
  • SEVIKAR 40 mg / 5 mg, film-coated tablet, box of 90
  • SEVIKAR 20 mg / 5 mg, film-coated tablet, box of 30
  • SEVIKAR 20 mg / 5 mg, film-coated tablet, box of 90

Composition

Active ingredientCoated tablet
Olmesartan medoxomil40 mg *
Amlodipine10 mg *

* per unit dose

Active ingredients: Olmesartan medoxomil , Amlodipine 
  • Excipients: Tablet core: Pregelatinized corn starch , Croscarmellose sodium , Magnesium stearate , Silicified
  • microcrystalline cellulose : Microcrystalline cellulose with , Colloidal anhydrous silica , Film coating: Polyvinyl alcohol , Macrogol 3350 , Talc , Titanium dioxide , Iron oxide yellow , Iron oxide red 
  • No excipient with known effect is not present in the composition of this drug

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

  • Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

  • General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

  • For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

  • It treats possible side effects and drug interactions that require attention and its effect on continuous use.
  • The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

Leave A Reply